ALTRETAMINE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for altretamine and what is the scope of patent protection?
Altretamine
is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. Additional information is available in the individual branded drug profile pages.There is one drug master file entry for altretamine.
Summary for ALTRETAMINE
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 107 |
| Clinical Trials: | 1 |
| Patent Applications: | 7,337 |
| DailyMed Link: | ALTRETAMINE at DailyMed |
Recent Clinical Trials for ALTRETAMINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Roswell Park Cancer Institute | Phase 1 |
| National Cancer Institute (NCI) | Phase 1 |
Medical Subject Heading (MeSH) Categories for ALTRETAMINE
Anatomical Therapeutic Chemical (ATC) Classes for ALTRETAMINE
US Patents and Regulatory Information for ALTRETAMINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | HEXALEN | altretamine | CAPSULE;ORAL | 019926-001 | Dec 26, 1990 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
